Source: DHSC 13.6.24
The Department of Health and Social Care has advised that Sanofi’s recombinant quadrivalent influenza
vaccine (QIVr) will not be available for this year’s flu vaccination programme. A letter (Statement of
amendment to the annual flu letter for 2024 to 2025 – 12 June 2024) explains that providers should order
alternative vaccine for adults based on the 2024 to 2025 influenza vaccine recommendations of the Joint
Committee on Vaccination and Immunisation (JCVI). See table 1 below.
2. For older adults this includes use of the high-dose quadrivalent influenza vaccine (QIV-HD) which will be
available in 2024 to 2025 in the UK market. Alternatively, further orders of other first line vaccines, the
adjuvanted quadrivalent influenza vaccine (aQIV) for those aged 65 years and older and cell-based
quadrivalent influenza vaccine (QIVc) for those under 65 years, should be made.
3.QIV-HD is licensed for those aged 60 years and over.
Click here for the source.
